Voyager Therapeutics, Inc. 8-K

What Happened

• On June 1, 2026, Voyager Therapeutics announced that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for VY1706, an investigational tau‑silencing gene therapy for Alzheimer’s disease (AD).
• The company plans a multi‑site, open‑label, dose‑escalation Phase 1 study expected to begin dosing in the second half of 2026. VY1706 will be given as a one‑time intravenous dose to adults with early AD who have tau pathology confirmed by PET imaging. The study may enroll up to 18 patients across three cohorts. The highest planned dose will not exceed 5 x 10^13 vector genomes/kg (the highest dose tested in non‑human primate GLP toxicology).

Key Details

• Filing date: June 1, 2026 (Form 8‑K).
• Trial design: multi‑site, open‑label, dose‑escalation; up to 18 patients in three cohorts.
• Administration: one‑time IV dose; highest dose ≤ 5 x 10^13 vg/kg.
• Endpoints: primary—safety and tolerability; secondary—effects on tau biology (CSF tau biomarkers and tau PET imaging).

Why It Matters

• IND clearance allows Voyager to start first‑in‑human testing of VY1706, marking a key clinical development milestone for its Alzheimer’s program. For investors, initiation of dosing in a human trial is a near‑term, observable event that can affect the company’s development timeline and potentially its valuation.
• The trial is small and early‑stage (safety‑focused); success in safety/tolerability would enable later efficacy testing, but the company’s filing highlights standard risks (enrollment, regulatory, safety, manufacturing, and cash needs). All timelines and plans are forward‑looking and subject to change per the company’s cautionary statements in the 8‑K.